LEXX Lexaria Bioscience Corp.: institutional ownership and insider trading
28 funds reported holding $1.06M of Lexaria Bioscience Corp. in their latest 13F filings; in Q2 2026 funds net bought $84.1K, with 6 new positions and 3 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market; over its last four quarters it reported revenue of $194K and net income of −$7.73M.
LEXX revenue and earnings
- Quarter ended May 31, 2026: revenue $0, net income −$1.99M, EPS -0.08
- Quarter ended Feb 28, 2026: revenue $20.0K, net income −$1.45M, EPS -0.06
- Quarter ended Nov 30, 2025: revenue $0, net income −$1.60M, EPS -0.07
- Quarter ended Aug 31, 2025: revenue $174K, net income −$2.70M, EPS -0.14
Famous investors holding LEXX
- Ken Griffin (Citadel Advisors): $87.9K, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $9.24K, 0.0% of the portfolio
Largest institutional holders of LEXX
- Invenomic Capital Management LP — $194K
- VANGUARD CAPITAL MANAGEMENT LLC — $167K
- VANGUARD GROUP INC — $160K
- GEODE CAPITAL MANAGEMENT, LLC — $140K
- CITADEL ADVISORS LLC — $87.9K
- TORONTO DOMINION BANK (TD, TDBCP) — $56.1K
- VANGUARD FIDUCIARY TRUST CO — $52.7K
- HRT FINANCIAL LP — $36.0K
- UBS Group AG (UBS) — $26.3K
- NORTHERN TRUST CORP (NTRS, NTRSO) — $22.3K
Recent LEXX insider trades
- Jul 30, 2025: Bunka Christopher bought 27,500 shares ($25.2K)
- Jul 29, 2025: McKechnie William Edward bought 5,000 shares ($4.55K)
- Jul 29, 2025: Docherty John Martin bought 5,376 shares ($5.00K)
- Jul 29, 2025: Carle Vanessa bought 750 shares ($683)